These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 11580885)

  • 1. Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure.
    Hollenberg NK
    Curr Hypertens Rep; 2001 Sep; 3 Suppl 1():S25-8. PubMed ID: 11580885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical profile of eprosartan.
    Puig JG; López MA; Bueso TS; Bernardino JI; Jiménez RT;
    Cardiovasc Drugs Ther; 2002 Dec; 16(6):543-9. PubMed ID: 12766389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential renoprotective effects of the angiotensin receptor blocker eprosartan: a review of preliminary renal studies.
    Rayner B; Jaeger B; Verboom CN; Pascoe M
    Cardiovasc J S Afr; 2004; 15(1):32-7. PubMed ID: 14997235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hypertension: the advent of a new angiotensin II receptor antagonist.
    Hedner T
    J Hypertens Suppl; 1999 Jun; 17(2):S21-5. PubMed ID: 10465063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
    Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
    Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
    Brodsky S; Gurbanov K; Abassi Z; Hoffman A; Ruffolo RR; Feuerstein GZ; Winaver J
    Hypertension; 1998 Oct; 32(4):746-52. PubMed ID: 9774374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical profile of eprosartan: a different angiotensin II receptor blocker.
    Blankestijn PJ; Rupp H
    Cardiovasc Hematol Agents Med Chem; 2008 Oct; 6(4):253-7. PubMed ID: 18855637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double blind randomized trial to compare the effects of eprosartan and enalapril on blood pressure, platelets, and endothelium function in patients with essential hypertension.
    Leu HB; Charng MJ; Ding PY
    Jpn Heart J; 2004 Jul; 45(4):623-35. PubMed ID: 15353873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical profile of the angiotensin II receptor blocker eprosartan.
    Hedner T
    J Hypertens Suppl; 2002 Jun; 20(5):S33-8. PubMed ID: 12184062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eprosartan for the treatment of hypertension.
    Ruilope L; Jäger B
    Expert Opin Pharmacother; 2003 Jan; 4(1):107-14. PubMed ID: 12517247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation in the angiotensin II receptor 1 blocker class on autonomic function.
    Krum H
    Curr Hypertens Rep; 2001 Sep; 3 Suppl 1():S17-23. PubMed ID: 11580884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation).
    Rahman ST; Lauten WB; Khan QA; Navalkar S; Parthasarathy S; Khan BV
    Am J Cardiol; 2002 Mar; 89(6):686-90. PubMed ID: 11897210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure.
    Brooks DP; Ruffolo RR
    J Hypertens Suppl; 1999 Jun; 17(2):S27-32. PubMed ID: 10465064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan.
    Gremmler B; Kunert M; Schleiting H; Ulbricht LJ
    Eur J Heart Fail; 2000 Jun; 2(2):183-7. PubMed ID: 10856732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A; Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and clinical efficacy of angiotensin receptor blockers.
    Sica DA
    Am J Hypertens; 2001 Jul; 14(7 Pt 2):242S-247S. PubMed ID: 11459213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eprosartan dual action offers clinical benefit for elderly and overweight hypertensives.
    Cardiovasc J S Afr; 2004; 15(2):91-2. PubMed ID: 15148545
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.